Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 10, 2017, Pages 1580-1588.e3

  Papamichael, Konstantinos ^a   Chachu, Karen A ^b   Vajravelu, Ravy K ^c   Vaughn, Byron P ^d   Ni, Josephine ^c   Osterman, Mark T ^c   Cheifetz, Adam S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

CD; Immunogenicity; Monitoring Therapy; Ulcerative Colitis

Indexed keywords

DRUG ANTIBODY; INFLIXIMAB; GASTROINTESTINAL AGENT;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK REDUCTION; ADOLESCENT; BLOOD; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; MULTICENTER STUDY; PROCEDURES; SERUM; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; DRUG MONITORING; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; RETROSPECTIVE STUDIES; SERUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85024862765     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2017.03.031     Document Type: Article

References (27)

1. Osterman, M.T., Haynes, K., Delzell, E., et al. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol 12 (2014), 811–817.
2. Ben-Horin, S., Chowers, Y., Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 33 (2011), 987–995.
3. Papamichael, K., Cheifetz, A.S., Use of anti-TNF drug concentrations to optimise patient management. Frontline Gastroenterol 7 (2016), 289–300.
4. Vaughn, B.P., Sandborn, W.J., Cheifetz, A.S., Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis 21 (2015), 1435–1442.
5. Nanda, K.S., Cheifetz, A.S., Moss, A.C., Impact of antibodies to infliximab on clinical outcomes and serum infliximab concentrations in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 108 (2013), 40–47.
6. Adedokun, O.J., Sandborn, W.J., Feagan, B.G., et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 147 (2014), 1296–1307.
7. Papamichael, K., Van Stappen, T., Vande Casteele, N., et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol 14 (2016), 543–549.
8. Cornillie, F., Hanauer, S.B., Diamond, R.H., et al. Postinduction serum infliximab trough concentration and decrease of C-reactive protein concentration are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 63 (2014), 1721–1727.
9. Papamichael, K., Baert, F., Tops, S., et al. Post-induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis. J Crohns Colitis 11 (2017), 53–59.
10. Ungar, B., Levy, I., Yavne, Y., et al. Optimizing anti-TNFα therapy: Serum concentrations of infliximab and adalimumab associate with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 14 (2016), 550–557.
11. Vande Casteele, N., Ferrante, M., Van Assche, G., et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148 (2015), 1320–1329.
12. Vaughn, B.P., Martinez-Vazquez, M., Patwardhan, V.R., et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 20 (2014), 1996–2003.
13. Taks, M., Pijls, P.A., Derijks, L.J., et al. The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 29 (2017), 169–173.
14. Steenholdt, C., Brynskov, J., Thomsen, O.O., et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 63 (2014), 919–927.
15. Steenholdt, C., Brynskov, J., Thomsen, O.O., et al. Individualized therapy is a long-term cost-effective method compared with dose intensification in Crohn's disease patients failing infliximab. Dig Dis Sci 60 (2015), 2762–2770.
16. Velayos, F.S., Kahn, J.G., Sandborn, W.J., et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 11 (2013), 654–666.
17. Singh, S., Heien, H.C., Sangaralingham, L.R., et al. Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn's disease. Clin Gastroenterol Hepatol 14 (2016), 1120–1129.
18. Fidder, H., Schnitzler, F., Ferrante, M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58 (2009), 501–508.
19. Afif, W., Loft us, E.V. Jr., Faubion, W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105 (2010), 1133–1139.
20. Wang, S.L., Ohrmund, L., Hauenstein, S., et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab concentrations in patient serum. J Immunol Methods 382 (2012), 177–188.
21. Van Assche, G., D'Haens, G., Noman, M., et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125 (2003), 1025–1031.
22. Capron, A., Haufroid, V., Wallemacq, P., Intra-cellular immunosuppressive drugs monitoring: A step forward toward better therapeutic efficacy after organ transplantation?. Pharmacol Res 111 (2016), 610–618.
23. Vande Casteele, N., Khanna, R., Levesque, B.G., et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 64 (2015), 1539–1545.
24. Yanai, H., Lichtenstein, L., Assa, A., et al. Concentrations of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 13 (2015), 522–530.
25. Vande Casteele, N., Gils, A., Singh, S., et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 108 (2013), 962–971.
26. Steenholdt, C., Bendtzen, K., Brynskov, J., et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 109 (2014), 1055–1064.
27. Billiet, T., Cleynen, I., Ballet, V., et al. Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience. Aliment Pharmacol Ther 44 (2016), 673–683.